Lexicon Pharmaceuticals Ownership
| LXRX Stock | USD 0.66 0.04 5.71% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 310.8 M | Current Value 361.5 M | Avarage Shares Outstanding 74.1 M | Quarterly Volatility 71.7 M |
Lexicon |
Lexicon Stock Ownership Analysis
About 84.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lexicon Pharmaceuticals recorded a loss per share of 0.74. The entity had not issued any dividends in recent years. The firm had 1:7 split on the 21st of May 2015. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. To find out more about Lexicon Pharmaceuticals contact Lonnel Coats at 281 863 3000 or learn more at https://www.lexpharma.com.Lexicon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lexicon Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lexicon Pharmaceuticals backward and forwards among themselves. Lexicon Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Lexicon Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nea Management Company, Llc | 2024-12-31 | 2.4 M | Ikarian Capital, Llc | 2024-12-31 | 1.6 M | Pinnacle Associates Inc | 2024-12-31 | 1.4 M | Northern Trust Corp | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | Nuveen Asset Management, Llc | 2024-09-30 | 1.1 M | Hennion & Walsh Asset Management Inc | 2024-12-31 | 863.3 K | Tang Capital Management Llc | 2024-12-31 | 850.3 K | Wellington Management Company Llp | 2024-12-31 | 748 K | Artal Group S A | 2024-12-31 | 136.2 M | Fmr Inc | 2024-12-31 | 52 M |
Lexicon Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexicon Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexicon Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lexicon Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexicon Pharmaceuticals Outstanding Bonds
Lexicon Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lexicon Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lexicon bonds can be classified according to their maturity, which is the date when Lexicon Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.